The 36-month beta value for ANTX is also noteworthy at -0.20. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ANTX is 19.38M, and at present, short sellers hold a 2.00% of that float. The average trading volume of ANTX on September 05, 2024 was 572.18K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ANTX) stock’s latest price update
AN2 Therapeutics Inc (NASDAQ: ANTX)’s stock price has gone decline by -6.36 in comparison to its previous close of 1.10, however, the company has experienced a -11.97% decrease in its stock price over the last five trading days. zacks.com reported 2024-08-19 that AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
ANTX’s Market Performance
ANTX’s stock has fallen by -11.97% in the past week, with a monthly drop of -58.96% and a quarterly drop of -49.51%. The volatility ratio for the week is 7.43% while the volatility levels for the last 30 days are 10.77% for AN2 Therapeutics Inc The simple moving average for the past 20 days is -20.86% for ANTX’s stock, with a -86.13% simple moving average for the past 200 days.
Analysts’ Opinion of ANTX
Many brokerage firms have already submitted their reports for ANTX stocks, with Leerink Partners repeating the rating for ANTX by listing it as a “Market Perform.” The predicted price for ANTX in the upcoming period, according to Leerink Partners is $1 based on the research report published on August 09, 2024 of the current year 2024.
Leerink Partners gave a rating of “Outperform” to ANTX, setting the target price at $5 in the report published on July 03rd of the current year.
ANTX Trading at -49.43% from the 50-Day Moving Average
After a stumble in the market that brought ANTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.36% of loss for the given period.
Volatility was left at 10.77%, however, over the last 30 days, the volatility rate increased by 7.43%, as shares sank -58.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.24% lower at present.
During the last 5 trading sessions, ANTX fell by -11.97%, which changed the moving average for the period of 200-days by -93.59% in comparison to the 20-day moving average, which settled at $1.2275. In addition, AN2 Therapeutics Inc saw -94.97% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANTX starting from RA Capital Healthcare Fund LP, who proposed sale 1,699,998 shares at the price of $1.00 back on Aug 15 ’24. After this action, RA Capital Healthcare Fund LP now owns shares of AN2 Therapeutics Inc, valued at $1,699,999 using the latest closing price.
RA Capital Nexus Fund II, L.P., the Affiliate of AN2 Therapeutics Inc, proposed sale 299,999 shares at $1.02 during a trade that took place back on Aug 15 ’24, which means that RA Capital Nexus Fund II, L.P. is holding shares at $305,998 based on the most recent closing price.
Stock Fundamentals for ANTX
Current profitability levels for the company are sitting at:
- -889.64 for the present operating margin
- 0.5 for the gross margin
The net margin for AN2 Therapeutics Inc stands at -808.21. The total capital return value is set at -0.72. Equity return is now at value -69.48, with -62.35 for asset returns.
Currently, EBITDA for the company is -69.64 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 49.61. The receivables turnover for the company is 0.27for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.61.
Conclusion
In summary, AN2 Therapeutics Inc (ANTX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
